Yahoo Finance

Estimated Discount To Fair Value: 49.8%

Tibet Rhodiola Pharmaceutical Holding is trading at CN¥38.61, significantly below its estimated fair value of CN¥76.93, highlighting its potential undervaluation based on cash flows. Despite a decrease in sales and net income for the first nine months of 2024 compared to the previous year, earnings are projected to grow at 25.71% annually over the next three years, with revenue growth expected to exceed market averages and a high forecasted return on equity of 29.9%.

• The growth report we've compiled suggests that Tibet Rhodiola Pharmaceutical Holding's future prospects could be on the up.

• Get an in-depth perspective on Tibet Rhodiola Pharmaceutical Holding's balance sheet by reading our health report here.

Systena

Overview: Systena Corporation operates in Japan, focusing on solution and framework design, IT services, business solutions, and cloud businesses, with a market cap of ¥127.97 billion.

Operations: The company's revenue is derived from solution and framework design, IT services, business solutions, and cloud businesses in Japan.

Estimated Discount To Fair Value: 21.1%

Systena is trading at ¥368, which is 21.1% below its estimated fair value of ¥466.4, indicating potential undervaluation based on cash flows. Earnings are projected to grow at 8.1% annually, outpacing the Japanese market's growth rate of 7.9%. Recent corporate guidance forecasts net sales up to ¥90 billion and operating profit up to ¥12 billion for fiscal year ending March 2025. The company also increased its dividend payments from the previous year.

• Our earnings growth report unveils the potential for significant increases in Systena's future results.

• Click here to discover the nuances of Systena with our detailed financial health report.

Key Takeaways

• Delve into our full catalog of 903 Undervalued Stocks Based On Cash Flows here.

• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1318 SHSE:600211 and TSE:2317.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com